{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:31:41Z","timestamp":1791232301867,"version":"4.1.0"},"reference-count":73,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Alzheimer's Disease"],"published-print":{"date-parts":[[2022,3,9]]},"abstract":"<jats:p>Background. Aducanumab, a new monoclonal antibody that targets \u03b2-amyloid aggregates, has been granted conditional approval by the U.S. FDA for treatment of mild Alzheimer\u2019s disease (AD). The approval of this drug without a confirmed significant clinical impact has resulted in several debates. Objective. In this narrative review, aducanumab approval-related controversy, the drug\u2019s pharmacokinetics and pharmacodynamic characteristics, evidence from the efficacy and safety trials of aducanumab, implications of the drug approval, and the future directions in the management of patients with AD are summarized. Methods. Using relevant keywords, Google Scholar, Web of Science, and MEDLINE databases and manufacturer\u2019s website were searched. Results. Infusion of aducanumab at a higher dose resulted in a modest slowing of cognitive decline among patients with mild cognitive impairment or early-onset AD dementia. The drug however can cause amyloid-related imaging abnormalities. Due to modest impact on cognition, the use of this drug by patients with AD will most likely be limited. The manufacturer is required to run an extended phase IIIb trial to verify the benefit of this drug. Access to therapy requires a careful selection of patients and periodic monitoring to ensure the optimal use of the drug. Conclusion. Despite the limitations, aducanumab is the first disease-modifying therapy approved for the treatment of AD. Aducanumab addresses a part of the pathogenesis of AD; therefore, drugs that can act on multiple targets are needed. In addition, the search for preventive strategies, validated plasma-based assays, and newer drugs for AD, which are effective, safe, convenient, and affordable, is vital.<\/jats:p>","DOI":"10.1155\/2022\/9343514","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T15:05:06Z","timestamp":1646838306000},"page":"1-10","source":"Crossref","is-referenced-by-count":58,"title":["Aducanumab Therapy to Treat Alzheimer\u2019s Disease: A Narrative Review"],"prefix":"10.1155","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4990-4783","authenticated-orcid":true,"given":"Semira Abdi","family":"Beshir","sequence":"first","affiliation":[{"name":"Clinical Pharmacy & Pharmacotherapeutics Department, Dubai Pharmacy College, Dubai, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4455-9872","authenticated-orcid":true,"given":"A. M.","family":"Aadithsoorya","sequence":"additional","affiliation":[{"name":"College of Medicine, Gulf Medical University, Ajman, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7861-5158","authenticated-orcid":true,"given":"Affana","family":"Parveen","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Gulf Medical University, Ajman, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3400-730X","authenticated-orcid":true,"given":"Sheron Sir Loon","family":"Goh","sequence":"additional","affiliation":[{"name":"Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6314-2485","authenticated-orcid":true,"given":"Nadia","family":"Hussain","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Al Ain University, Al Ain, Abu Dhabi, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2030-0962","authenticated-orcid":true,"given":"Vineetha Bharathan","family":"Menon","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, Gulf Medical University, Ajman, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"1","volume-title":"Dementia","author":"World Health Organization","year":"2021"},{"key":"2","article-title":"Dementia statistics","year":"2021","journal-title":"Alzheimer\u2019s Disease International"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-020-00391-7"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.235112"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.03.21267235"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.16-3-247"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2016.1241232"},{"key":"8","volume-title":"Discovery of aducanumab","author":"Neurimmune","year":"2020"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1159\/000511506"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n156"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12312"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00838-z"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30480-6"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12213"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105754"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1126\/science.1566067"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24501-0"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1038\/nature19323"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1002\/prot.25978"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2016.06.002"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224"},{"key":"22","volume-title":"Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket","author":"Alzheimer\u2019s Association","year":"2020"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1503"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1097\/01.nt.0000725248.82870.33"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3854"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113945"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1016\/s2215-0366(21)00197-8"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1682"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-01546-2"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000587"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14484"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160122"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12155"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.15286"},{"key":"35","article-title":"Single and multiple ascending dose study of aducanumab (BIIB037) in Japanese participants with Alzheimer\u2019s disease","author":"B. Inc","year":"2020"},{"key":"36","article-title":"ADUHELM ICARE AD-US Study, the first real-world observational phase 4 study in Alzheimer\u2019s disease at AAIC 2021","author":"L. Biogen","year":"2021","journal-title":"Biogen"},{"key":"37","article-title":"Absolute bioavailability of a single, fixed subcutaneous dose of aducanumab in healthy participants","author":"L. Biogen Inc","year":"2017"},{"key":"38","article-title":"A study to assess absolute bioavailability of aducanumab in healthy volunteers","author":"L. Biogen Inc","year":"2021"},{"key":"39","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-017-0355-7"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0000000000000144"},{"key":"41","article-title":"A study of aducanumab in participants with mild cognitive impairment due to Alzheimer\u2019s disease or with mild Alzheimer\u2019s disease dementia to evaluate the safety of continued dosing in participants with asymptomatic amyloid-related imaging abnormalities","author":"B. Inc","year":"2020"},{"key":"42","article-title":"221AD302 phase 3 study of aducanumab BIIB037 in early Alzheimer\u2019s disease","author":"B. Inc","year":"2021"},{"key":"43","article-title":"221AD301 phase 3 study of aducanumab BIIB037 in early Alzheimer\u2019s disease","author":"B. Inc","year":"2020"},{"key":"44","article-title":"Biogen and Eisai to discontinue phase 3 ENGAGE and EMERGE trials of aducanumab in Alzheimer\u2019s disease","author":"B. Inc","year":"2019","journal-title":"Biogen"},{"key":"45","article-title":"Aducanumab update","author":"B. Inc","year":"2019","journal-title":"Investors Conference"},{"key":"46","doi-asserted-by":"publisher","DOI":"10.1002\/alz.047259"},{"key":"47","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12286"},{"key":"48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2019.09.075"},{"key":"49","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4161"},{"key":"50","article-title":"A study to evaluate safety and tolerability of aducanumab in participants with Alzheimer\u2019s disease who had previously participated in the aducanumab studies 221AD103, 221AD301, 221AD302 and 221AD205","author":"B. Inc","year":"2021"},{"key":"51","doi-asserted-by":"publisher","DOI":"10.3233\/adr-190143"},{"key":"52","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12816"},{"key":"53","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12283"},{"key":"54","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11010014"},{"key":"55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"56","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2019.1683160"},{"issue":"6","key":"57","article-title":"Therapeutic focus the future of treating Alzheimer\u2019s disease: aducanumab & beyond","volume":"20","author":"H. Russ","year":"2020","journal-title":"Drug Development & Delivery"},{"key":"58","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.00025"},{"key":"59","doi-asserted-by":"publisher","DOI":"10.1007\/BF00308809"},{"key":"60","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-141959"},{"key":"61","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.3812"},{"key":"62","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-190256"},{"key":"63","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-179935"},{"key":"64","doi-asserted-by":"publisher","DOI":"10.34133\/2019\/5341375"},{"key":"65","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2016.10.012"},{"key":"66","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201606210"},{"key":"67","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-021-00070-2"},{"key":"68","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-200413"},{"key":"69","doi-asserted-by":"publisher","DOI":"10.1159\/000348347"},{"key":"70","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-181001"},{"key":"71","doi-asserted-by":"publisher","DOI":"10.1080\/02648725.2018.1523521"},{"key":"72","doi-asserted-by":"publisher","DOI":"10.1055\/a-0955-9587"},{"key":"73","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2015.00191"}],"container-title":["International Journal of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/ijad\/2022\/9343514.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ijad\/2022\/9343514.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ijad\/2022\/9343514.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T15:05:16Z","timestamp":1646838316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/ijad\/2022\/9343514\/"}},"subtitle":[],"editor":[{"given":"giulia","family":"abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":73,"alternative-id":["9343514","9343514"],"URL":"https:\/\/doi.org\/10.1155\/2022\/9343514","relation":{},"ISSN":["2090-0252","2090-8024"],"issn-type":[{"value":"2090-0252","type":"electronic"},{"value":"2090-8024","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,9]]}}}